| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 06/02/2005 | US20050118288 Method for producing high-quality hydropbic licorice extract |
| 06/02/2005 | US20050118263 Composition |
| 06/02/2005 | US20050118242 Using testosterone; topical applying to skins |
| 06/02/2005 | US20050118232 N-acyl-phosphatidyl-ethanolamines and/or mixtures of n-acyl-ethanolamines with phosphatidic acids or lysophosphatidic acids |
| 06/02/2005 | US20050118168 Administering a compound which binds to a C-type lectin on the surface of a dendritic cell, with the proviso that the C-type lectin is not the DEC-205 receptor |
| 06/02/2005 | CA2545726A1 Use of interferon tau for the treatment of obesity and for promotion of weight loss |
| 06/02/2005 | CA2545514A1 Combination of a dpp iv inhibitor and an antiobesity or appetite regulating agent |
| 06/02/2005 | CA2544230A1 Combinations of at1-antagonists, amiloride or triamterine, and a diuretic |
| 06/02/2005 | CA2543247A1 Benzannelated compounds as ppar activators |
| 06/02/2005 | CA2543239A1 Heteroaryl derivatives as ppar activators |
| 06/01/2005 | EP1535920A1 Process for preparation of 1,3-benzodioxole-2-spiro- cycloalkane derivatives |
| 06/01/2005 | EP1535919A2 Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities |
| 06/01/2005 | EP1535915A1 Furan or thiophene derivative and medicinal use thereof |
| 06/01/2005 | EP1535913A1 Novel quaternary ammonium compounds |
| 06/01/2005 | EP1535907A1 Benzenesulfonate of 4-fluoro-2-cyanopyrrolidine derivative |
| 06/01/2005 | EP1535906A1 Nitrogen-containing compounds |
| 06/01/2005 | EP1535630A1 Preventive for the onset of diabetes |
| 06/01/2005 | EP1535614A2 Materials and methods for detection and treatment of immune system dysfunctions |
| 06/01/2005 | EP1535613A2 Polymorphic form of atorvastatin calcium |
| 06/01/2005 | EP1535512A1 DISEASE MODEL ANIMAL CARRYING FOREIGN PPARa GENE TRANSFERRED THEREINTO AND USE THEREOF |
| 06/01/2005 | EP1534807A1 A process for decreasing the amount of cholesterol in a marine oil using a volatile working fluid |
| 06/01/2005 | EP1534728A2 Antisense modulation of glucocorticoid receptor expression |
| 06/01/2005 | EP1534725A2 Compounds and methods for inhibiting selectin-mediated function |
| 06/01/2005 | EP1534720A1 Mitochondrially targeted antioxidants |
| 06/01/2005 | EP1534708A2 Purine derivatives and their use as antiproliferative agents |
| 06/01/2005 | EP1534707A1 Substituted 2,4-dihydro-pyrrolo (3, 4-b) -quinolin-9-one derivatives useful as phosphodiesterase inhibitors |
| 06/01/2005 | EP1534704A1 Process for preparing 5-(4-fluorophenyl)-1-[2-((2r,4r)-4-hydroxy -6-oxo-tetrahydro-pyran-2-yl)ethyl]-2-isopropyl-4-phenyl-1h-pyrrole-3-carboxylic acid phenylamide |
| 06/01/2005 | EP1534703A2 Antagonists of melanin concentrating hormone receptor |
| 06/01/2005 | EP1534695A2 Tyrosine kinase inhibitors |
| 06/01/2005 | EP1534687A1 Pyrimidine compounds |
| 06/01/2005 | EP1534681A1 Substituted quinoline ccr5 receptor antagonists |
| 06/01/2005 | EP1534679A2 Inhibitors of post-amadori advanced glycation end products |
| 06/01/2005 | EP1534677A1 Piperidine derivatives and their use as selective inhibitors of mip-1alpha binding to its receptor ccr1 |
| 06/01/2005 | EP1534676A1 Piperidinetriol derivatives as inhibitors of glycosylceramide synthase |
| 06/01/2005 | EP1534668A1 Crystalline solid form of (2s-5z)-2-amino-7-(ethanimidoylamino)-2-methylhept-5-enoic acid |
| 06/01/2005 | EP1534667A1 Muscarinic agonists |
| 06/01/2005 | EP1534666A1 Compounds for modulating the glycolosis enzyme complex and/or transaminase complex |
| 06/01/2005 | EP1534663A1 N-bridged selective androgen receptor modulators and methods of use thereof |
| 06/01/2005 | EP1534391A1 Novel piperazinyl-pyrazinone derivatives for the treatment of 5-ht2a receptor-related disorders |
| 06/01/2005 | EP1534389A2 Pyrazolopyrimidines as kinase inhibitors |
| 06/01/2005 | EP1534322A1 Minibrain homologous proteins involved in the regulation of energy homeostasis |
| 06/01/2005 | EP1534314A1 A nutritional and therapeutic composition of an insulin sensitizer and a peptide fraction |
| 06/01/2005 | EP1534298A2 Novel anticholesterol compositions and method for using same |
| 06/01/2005 | EP1534290A2 Novel inhibitors of kinases |
| 06/01/2005 | EP1534289A1 Adenosine a2a receptor antagonists for treating restless legs syndrome or related disorders |
| 06/01/2005 | EP1534280A1 Aryl piperidine derivatives and use thereof to reduce elevated levels of ldl-cholesterol |
| 06/01/2005 | EP1534278A2 Nitrosated proton pump inhibitors, compositions and methods of use |
| 06/01/2005 | EP1534277A1 Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals |
| 06/01/2005 | EP1534275A1 Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals |
| 06/01/2005 | EP1534264A2 Compounds that modulate the activity of ptp-1b and tc-ptp |
| 06/01/2005 | EP1534263A2 Novel compounds, pharmaceutical compositions containing same, and methods of use for same |
| 06/01/2005 | EP1534260A2 Perfluorinated fatty acids for the treatment of obesity, diabetes, hyperlipidaemia, cancer and inflammation |
| 06/01/2005 | EP1534256A2 Immunomodulation and effect on cell processes relating to serotonin family receptors and the blood-brain barrier |
| 06/01/2005 | EP1534250A2 Electrospun amorphous pharmaceutical compositions |
| 06/01/2005 | EP1534248A1 Lasofoxifene tablet and its coating |
| 06/01/2005 | EP1534074A2 Combination therapy for the treatment of obesity |
| 06/01/2005 | EP1453820B1 Substituted 6h-dibenzo[c,h]chromenes as estrogenic agents |
| 06/01/2005 | EP1423002A4 Use of cross-linked, covalently bound urokinase plasminogen activator (scupa)-urokinase plasminogen activator receptor (supar) complex as a fibrinolytic agent |
| 06/01/2005 | EP1347760B1 Nmda receptor agonist pharmaceutical compositions |
| 06/01/2005 | EP1345902B1 Substituted heterocyclo-norbornylamine derivatives, method for producing the same, their use as medicament or diagnostic agent and medicament containing the same |
| 06/01/2005 | EP1268465B1 Triarylimidazole derivatives as cytokine inhibitors |
| 06/01/2005 | EP1233951B1 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors |
| 06/01/2005 | EP1207157B1 Substituted benzylthiazolidine-2,4-dione derivatives |
| 06/01/2005 | EP1178977B1 Ion channel modulating agents |
| 06/01/2005 | EP1173205B1 An oral formulation for ileum administering comprising an inhibitor compound of the ileal bile acid transport |
| 06/01/2005 | EP1148871B1 Core tablet for controlled release of gliclazide after oral administration |
| 06/01/2005 | EP1115695B1 (r)-chiral halogenated 1-substitutedamino-(n+1)-alkanols useful for inhibiting cholesteryl ester transfer protein activity |
| 06/01/2005 | EP1095015B1 Sulfonylamino carboxylic acid n-arylamides as guanylate cyclase activators |
| 06/01/2005 | EP1062210B1 1,2-diazepane derivatives as interleukin-1beta converting enzyme inhibitors |
| 06/01/2005 | EP1049679B1 Sulphonamide derivatives for treatment of cns disorders |
| 06/01/2005 | EP1003744B1 4-AMINOPYRROLE(3,2-d) PYRIMIDINES AS NEUROPEPTIDE Y RECEPTOR ANTAGONISTS |
| 06/01/2005 | CN1622957A IFNAR2 mutants, their production and use |
| 06/01/2005 | CN1622946A Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors |
| 06/01/2005 | CN1622945A Thiazolidinedione derivatives and pharmaceutical composition comprising the same |
| 06/01/2005 | CN1622941A Glutaminyl based DPIV inhibitors |
| 06/01/2005 | CN1622937A Process for the manufacture of HMG-coa reductase inhibitors |
| 06/01/2005 | CN1622816A Composition and method for augmenting kidney function |
| 06/01/2005 | CN1622760A A process for the extraction, purification and enzymatic modification of soy 7S globulin alpha' subunit for use as hypocholesterolemizing agent |
| 06/01/2005 | CN1621526A Recombinant adeno-associated virus for prevention and cure of I-type diabetes and use thereof |
| 06/01/2005 | CN1621404A Drug and method for regulating cholesterol and triglyceride |
| 06/01/2005 | CN1621085A Medicine for treating diabetes |
| 06/01/2005 | CN1620937A Pure traditional Chinese herbal drink preparation method |
| 06/01/2005 | CN1620905A Preparation method and uses of pumpkin polysaccharide healthcare food |
| 06/01/2005 | CN1204138C Pyrazolo [4, 3-d] pyrimidine derivs. |
| 06/01/2005 | CN1204057C Multielement mineral water and its preparation method |
| 06/01/2005 | CN1203899C Compounds with chelation affinity and selectivity for first transition series elements, and their use in medical therapy |
| 06/01/2005 | CN1203890C Medicine for treating and preventing hypertension and hyperlipemia and its preparation |
| 06/01/2005 | CN1203878C Organic state micro element supplement agent |
| 06/01/2005 | CN1203866C Soluble nutritious powder with multiple elements, vitamins and amino acids and its preparation method |
| 06/01/2005 | CN1203858C Pharmaceutically active morpholinol |
| 06/01/2005 | CN1203852C Valdecoxib compositions |
| 06/01/2005 | CN1203850C Effervescent vitamin C granule and its preparation method |
| 06/01/2005 | CN1203846C Biphasic controlled release delivery system for high solubility pharmaceuticals and method |
| 06/01/2005 | CN1203784C Preparation of manganese-enriched nutrient reinforcer |
| 05/31/2005 | US6900344 Method of preparing alkylated salicylamides via a dicarboxylate intermediate |
| 05/31/2005 | US6900334 Antiallergens; autoimmune diseases |
| 05/31/2005 | US6900329 MCH antagonists and their use in the treatment of obesity |
| 05/31/2005 | US6900327 Used as antidepressants, to treat obsessive compulsive disorder, panic disorders, bulimia, anorexia, pain, obesity, senile demential, migraines, and social phobias |
| 05/31/2005 | US6900318 1,4,5,6-tetrahydropyrimidine derivative as a vitronectin inhibitor |
| 05/31/2005 | US6900309 Aminocarbonylation reaction of a adenosine compound containing purine base and pentofuranosyl sugar and a leaving group at 2 position of purine ring, with an amine compound in presence of carbon monoxide and suitable coupling catalyst |